Gastritis, duodenitis, upper gastrointestinal bleeding, gastric ulcer, abdominal pain, bloody stool, vomiting, anemia
Conditions
Interventions
Experimental group (7-12 years old):Ciprofol was given intravenously at an initial dose of 0.6 mg/kg
Sponsors
The Second Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
7 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 7 to 12 years. 2. Body mass index (BMI) ranges: 14.0-19.3 kg/m^2 for ages 5-7 years, 14.7-20.4 kg/m^2 for ages 8-10 years, and 15.4-22.4 kg/m^2 for ages 11-12 years. 3. American Society of Anesthesiologists (ASA) physical status classification I-II. 4. Normal developmental status. 5. Informed consent was obtained from the legal guardians of the children prior to anesthesia.
Exclusion criteria
Exclusion criteria: 1.Allergy to ciprofol or propofol or lidocaine. 2.Confirmed difficult airway. 3.Ongoing sedative therapy (e.g., propofol, morphine, fentanyl, sufentanil, midazolam, dexmedetomidine, ketamine) or recent use of sedatives (withdrawal time <24 hours). 4.Cardiac or respiratory diseases. 5.Hepatic or renal dysfunction. 6.Developmental malformations or delays. 7.If any of the above answers is "No," the subject is excluded from participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ED50 and ED95 of ciprofol for suppressing the gastroscope insertion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgeon satisfaction;Family satisfaction;Anesthesia Indicators;Hemodynamic Parameters;Surgical indicators;Rate of adverse reactions; | — |
Countries
China
Contacts
Public ContactZeng Ruifeng
The Second Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed